Jing Pan, Yue Tan, Guoling Wang, Biping Deng, Zhuojun Ling, Weiliang Song, Samuel Seery, Yanlei Zhang, Shuixiu Peng, Jinlong Xu, Jiajia Duan, Zelin Wang, Xinjian Yu, Qinlong Zheng, Xiuwen Xu, Ying Yuan, Fangrong Yan, Zhenglong Tian, Kaiting Tang, Jiecheng Zhang, Alex H Chang, Xiaoming Feng
PURPOSE: Patients with relapsed or refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) have few options and poor prognosis. The aim was to assess donor-derived anti-CD7 chimeric antigen receptor (CAR) T-cell safety and efficacy in patients with r/r T-ALL. METHODS: In this single-center, phase I trial, we administered anti-CD7 CAR T cells, manufactured from either previous stem-cell transplantation donors or new donors, to patients with r/r T-ALL, in single infusions at doses of 5 × 105 or 1 × 106 (±30%) cells per kilogram of body weight...
July 29, 2021: Journal of Clinical Oncology
Harold J Burstein, Mark R Somerfield, Debra L Barton, Ali Dorris, Lesley J Fallowfield, Dharamvir Jain, Stephen R D Johnston, Larissa A Korde, Jennifer K Litton, Erin R Macrae, Lindsay L Peterson, Praveen Vikas, Rachel L Yung, Hope S Rugo
PURPOSE: To update recommendations of the ASCO systemic therapy for hormone receptor (HR)-positive metastatic breast cancer (MBC) guideline. METHODS: An Expert Panel conducted a systematic review to identify new, potentially practice-changing data. RESULTS: Fifty-one articles met eligibility criteria and form the evidentiary basis for the recommendations. RECOMMENDATIONS: Alpelisib in combination with endocrine therapy (ET) should be offered to postmenopausal patients, and to male patients, with HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA -mutated, ABC, or MBC following prior endocrine therapy with or without a cyclin-dependent kinase (CDK) 4/6 inhibitor...
July 29, 2021: Journal of Clinical Oncology
Beverly Moy, R Bryan Rumble, Steven E Come, Nancy E Davidson, Angelo Di Leo, Julie R Gralow, Gabriel N Hortobagyi, Douglas Yee, Ian E Smith, Mariana Chavez-MacGregor, Rita Nanda, Heather L McArthur, Laura Spring, Katherine E Reeder-Hayes, Kathryn J Ruddy, Paul S Unger, Shaveta Vinayak, William J Irvin, Avan Armaghani, Michael A Danso, Natalie Dickson, Sophie S Turner, Cheryl L Perkins, Lisa A Carey
PURPOSE: This guideline updates recommendations of the ASCO guideline on chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer (MBC) that is either endocrine-pretreated or hormone receptor (HR)-negative. METHODS: An Expert Panel conducted a targeted systematic literature review guided by a signals approach to identify new, potentially practice-changing data that might translate into revised guideline recommendations...
July 29, 2021: Journal of Clinical Oncology
Meredith S Irwin, Arlene Naranjo, Fan F Zhang, Susan L Cohn, Wendy B London, Julie M Gastier-Foster, Nilsa C Ramirez, Ruthann Pfau, Shalini Reshmi, Elizabeth Wagner, Jed Nuchtern, Shahab Asgharzadeh, Hiroyuki Shimada, John M Maris, Rochelle Bagatell, Julie R Park, Michael D Hogarty
PURPOSE: Treatment planning for children with neuroblastoma requires accurate assessment of prognosis. The most recent Children's Oncology Group (COG) risk classification system used tumor stage as defined by the International Neuroblastoma Staging System. Here, we validate a revised classifier using the International Neuroblastoma Risk Group Staging System (INRGSS) and incorporate segmental chromosome aberrations (SCA) as an additional genomic biomarker. METHODS: Newly diagnosed patients enrolled on the COG neuroblastoma biology study ANBL00B1 between 2007 and 2017 with known age, International Neuroblastoma Staging System, and INRGSS stage were identified (N = 4,832)...
July 28, 2021: Journal of Clinical Oncology
Michel Bolla, Anouk Neven, Philippe Maingon, Christian Carrie, Ana Boladeras, Demetrios Andreopoulos, Antoine Engelen, Santhanam Sundar, Elzbieta M van der Steen-Banasik, John Armstrong, Karine Peignaux-Casasnovas, Jihane Boustani, Fernanda G Herrera, Bradley R Pieters, Annerie Slot, Amit Bahl, Christopher D Scrase, David Azria, Jan Jansa, Joe M O'Sullivan, Alphonsus C M Van Den Bergh, Laurence Collette
PURPOSE: The European Organisation for Research and Treatment of Cancer (EORTC) trial 22991 (NCT00021450) showed that 6 months of concomitant and adjuvant androgen suppression (AS) improves event- (EFS, Phoenix) and clinical disease-free survival (DFS) of intermediate- and high-risk localized prostatic carcinoma, treated by external-beam radiotherapy (EBRT) at 70-78 Gy. We report the long-term results in intermediate-risk patients treated with 74 or 78 Gy EBRT, as per current guidelines...
July 26, 2021: Journal of Clinical Oncology
Deborah M Stephens
No abstract text is available yet for this article.
July 26, 2021: Journal of Clinical Oncology
John C Byrd, Peter Hillmen, Paolo Ghia, Arnon P Kater, Asher Chanan-Khan, Richard R Furman, Susan O'Brien, Mustafa Nuri Yenerel, Arpad Illés, Neil Kay, Jose A Garcia-Marco, Anthony Mato, Javier Pinilla-Ibarz, John F Seymour, Stephane Lepretre, Stephan Stilgenbauer, Tadeusz Robak, Wayne Rothbaum, Raquel Izumi, Ahmed Hamdy, Priti Patel, Kara Higgins, Sophia Sohoni, Wojciech Jurczak
PURPOSE: Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We conducted an open-label, randomized, noninferiority, phase III trial comparing acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia (CLL). METHODS: Patients with previously treated CLL with centrally confirmed del(17)(p13.1) or del(11)(q22.3) were randomly assigned to oral acalabrutinib 100 mg twice daily or ibrutinib 420 mg once daily until progression or unacceptable toxicity...
July 26, 2021: Journal of Clinical Oncology
Robin Kate Kelley, Bruno Sangro, William Harris, Masafumi Ikeda, Takuji Okusaka, Yoon-Koo Kang, Shukui Qin, David W-M Tai, Ho Yeong Lim, Thomas Yau, Wei-Peng Yong, Ann-Lii Cheng, Antonio Gasbarrini, Silvia Damian, Jordi Bruix, Mitesh Borad, Johanna Bendell, Tae-You Kim, Nathan Standifer, Philip He, Mallory Makowsky, Alejandra Negro, Masatoshi Kudo, Ghassan K Abou-Alfa
PURPOSE: This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unresectable hepatocellular carcinoma (HCC), including a novel regimen featuring a single, priming dose of tremelimumab ( identifier: NCT02519348). PATIENTS AND METHODS: Patients with HCC who had progressed on, were intolerant to, or refused sorafenib were randomly assigned to receive T300 + D (tremelimumab 300 mg plus durvalumab 1,500 mg [one dose each during the first cycle] followed by durvalumab 1,500 mg once every 4 weeks), durvalumab monotherapy (1,500 mg once every 4 weeks), tremelimumab monotherapy (750 mg once every 4 weeks [seven doses] and then once every 12 weeks), or T75 + D (tremelimumab 75 mg once every 4 weeks plus durvalumab 1,500 mg once every 4 weeks [four doses] followed by durvalumab 1,500 mg once every 4 weeks)...
July 22, 2021: Journal of Clinical Oncology
Michael T Halpern, Janet S de Moor, K Robin Yabroff
PURPOSE: Although pain is a frequently reported symptom among individuals with cancer, there is limited information on the impact of pain on employment or financial outcomes. This study used nationally representative data to examine the role of pain levels on employment and financial outcomes. METHODS: We used data from the 2016-2017 Medical Expenditure Panel Survey Experiences with Cancer Survivorship Supplement to identify 1,213 adults diagnosed with cancer. Multivariable logistic regression analyses were used to examine association of pain levels and self-reported employment and financial outcomes...
July 22, 2021: Journal of Clinical Oncology
Nicholas J Boddicker, Chunling Hu, Jeffrey N Weitzel, Peter Kraft, Katherine L Nathanson, David E Goldgar, Jie Na, Hongyan Huang, Rohan D Gnanaolivu, Nicole Larson, Amal Yussuf, Song Yao, Celine M Vachon, Amy Trentham-Dietz, Lauren Teras, Jack A Taylor, Christopher E Scott, Dale P Sandler, Tina Pesaran, Alpa V Patel, Julie R Palmer, Irene M Ong, Janet E Olson, Katie O'Brien, Susan Neuhausen, Elena Martinez, Huiyan Ma, Sara Lindstrom, Loic Le Marchand, Charles Kooperberg, Rachid Karam, David J Hunter, James M Hodge, Christopher Haiman, Mia M Gaudet, Chi Gao, Holly LaDuca, James V Lacey, Jill S Dolinsky, Elizabeth Chao, Brian D Carter, Elizabeth S Burnside, Kimberly A Bertrand, Leslie Bernstein, Paul W Auer, Christine Ambrosone, Siddhartha Yadav, Steven N Hart, Eric C Polley, Susan M Domchek, Fergus J Couch
PURPOSE: The prevalence of germline pathogenic variants (PVs) in established breast cancer predisposition genes in women in the general population over age 65 years is not well-defined. However, testing guidelines suggest that women diagnosed with breast cancer over age 65 years might have < 2.5% likelihood of a PV in a high-penetrance gene. This study aimed to establish the frequency of PVs and remaining risks of breast cancer for each gene in women over age 65 years. METHODS: A total of 26,707 women over age 65 years from population-based studies (51...
July 22, 2021: Journal of Clinical Oncology
Andrea C Enzinger, Kaushik Ghosh, Nancy L Keating, David M Cutler, Mary Beth Landrum, Alexi A Wright
PURPOSE: Heightened regulations have decreased opioid prescribing across the United States, yet little is known about trends in opioid access among patients dying of cancer. METHODS: Among 270,632 Medicare fee-for-service decedents with poor prognosis cancers, we used part D data to examine trends from 2007 to 2017 in opioid prescription fills and opioid potency (morphine milligram equivalents per day [MMED]) near the end-of-life (EOL), defined as the 30 days before death or hospice enrollment...
July 22, 2021: Journal of Clinical Oncology
Laetitia Dahan, Nicolas Williet, Karine Le Malicot, Jean-Marc Phelip, Jérôme Desrame, Olivier Bouché, Caroline Petorin, David Malka, Christine Rebischung, Thomas Aparicio, Cédric Lecaille, Yves Rinaldi, Anthony Turpin, Anne-Laure Bignon, Jean-Baptiste Bachet, Jean-François Seitz, Come Lepage, Eric François
PURPOSE: Metastatic pancreatic cancer (mPC) still harbors a dismal prognosis. Our previous trial (PRODIGE 4-ACCORD 11) demonstrated the superiority of 6-month chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) over gemcitabine for overall survival. The high limiting oxaliplatin-related neurotoxicity supports the evaluation of an oxaliplatin stop-and-go strategy and a sequential strategy in mPC. METHODS: In this phase II study, patients were randomly assigned to receive either 6 months of FOLFIRINOX (arm A), 4 months of FOLFIRINOX followed by leucovorin plus fluorouracil maintenance treatment for controlled patients (arm B), or a sequential treatment alternating gemcitabine and fluorouracil, leucovorin, and irinotecan every 2 months (arm C)...
July 21, 2021: Journal of Clinical Oncology
Valeria Mercadante, Siri Beier Jensen, Derek K Smith, Kari Bohlke, Jessica Bauman, Michael T Brennan, Robert P Coppes, Niels Jessen, Narinder K Malhotra, Barbara Murphy, David I Rosenthal, Arjan Vissink, Jonn Wu, Deborah P Saunders, Douglas E Peterson
PURPOSE: To provide evidence-based recommendations for prevention and management of salivary gland hypofunction and xerostomia induced by nonsurgical cancer therapies. METHODS: Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and ASCO convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. PubMed, EMBASE, and Cochrane Library were searched for randomized controlled trials published between January 2009 and June 2020...
July 20, 2021: Journal of Clinical Oncology
AnnaLynn M Williams, Kevin R Krull, Carrie R Howell, Pia Banerjee, Tara M Brinkman, Sue C Kaste, Robyn E Partin, Deokumar Srivastava, Yutaka Yasui, Gregory T Armstrong, Leslie L Robison, Melissa M Hudson, Kirsten K Ness
PURPOSE: Eight percent of young-adult childhood cancer survivors meet criteria for frailty, an aging phenotype associated with poor health. In the elderly general population, frailty is associated with neurocognitive decline; this association has not been examined in adult survivors of childhood cancer. METHODS: Childhood cancer survivors 18-45 years old (≥ 10 years from diagnosis) were clinically evaluated for prefrailty or frailty (respectively defined as ≥ 2 or ≥ 3 of: muscle wasting, muscle weakness, low energy expenditure, slow walking speed, and exhaustion [Fried criteria]) and completed neuropsychologic assessments at enrollment (January 2008-June 2013) and 5 years later...
July 20, 2021: Journal of Clinical Oncology
Nicolaus Kröger, Katja Sockel, Christine Wolschke, Wolfgang Bethge, Richard F Schlenk, Dominik Wolf, Michael Stadler, Guido Kobbe, Gerald Wulf, Gesine Bug, Kerstin Schäfer-Eckart, Christof Scheid, Florian Nolte, Jan Krönke, Matthias Stelljes, Dietrich Beelen, Marion Heinzelmann, Detlef Haase, Hannes Buchner, Gabriele Bleckert, Aristoteles Giagounidis, Uwe Platzbecker
PURPOSE: In contrast to 5-azacytidine (5-aza), allogeneic stem-cell transplantation (HSCT) represents a curative treatment strategy for patients with myelodysplastic syndromes (MDS), but therapy-related mortality (TRM) limits its broader use in elderly patients with MDS. The present prospective multicenter study compared HSCT following 5-aza pretreatment with continuous 5-aza treatment in patients with higher-risk MDS age 55-70 years. METHODS: One hundred ninety patients with a median age of 63 years were enrolled...
July 20, 2021: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Elihu Estey, Moshe Talpaz, Hagop Kantarjian
No abstract text is available yet for this article.
July 19, 2021: Journal of Clinical Oncology
Muriel Brackstone, Fulvia G Baldassarre, Francisco E Perera, Tulin Cil, Mariana Chavez Mac Gregor, Ian S Dayes, Jay Engel, Janet K Horton, Tari A King, Anat Kornecki, Ralph George, Sandip K SenGupta, Patricia A Spears, Andrea F Eisen
PURPOSE: To provide recommendations on the best strategies for the management and on the best timing and treatment (surgical and radiotherapeutic) of the axilla for patients with early-stage breast cancer. METHODS: Ontario Health (Cancer Care Ontario) and ASCO convened a Working Group and Expert Panel to develop evidence-based recommendations informed by a systematic review of the literature. RESULTS: This guideline endorsed two recommendations of the ASCO 2017 guideline for the use of sentinel lymph node biopsy in patients with early-stage breast cancer and expanded on that guideline with recommendations for radiotherapy interventions, timing of staging after neoadjuvant chemotherapy (NAC), and mapping modalities...
July 19, 2021: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Steven G DuBois, M Meaghan Granger, Susan Groshen, Denice Tsao-Wei, Lingyun Ji, Anasheh Shamirian, Scarlett Czarnecki, Fariba Goodarzian, Rachel Berkovich, Hiroyuki Shimada, Judith G Villablanca, Kieuhoa T Vo, Navin Pinto, Yael P Mosse, John M Maris, Suzanne Shusterman, Susan L Cohn, Kelly C Goldsmith, Brian Weiss, Gregory A Yanik, Clare J Twist, Meredith S Irwin, Daphne A Haas-Kogan, Julie R Park, Araz Marachelian, Katherine K Matthay
PURPOSE: 131 I-metaiodobenzylguanidine (MIBG) is an active radiotherapeutic for neuroblastoma. The primary aim of this trial was to identify which of three MIBG regimens was likely associated with the highest true response rate. PATIENTS AND METHODS: Patients 1-30 years were eligible if they had relapsed or refractory neuroblastoma, at least one MIBG-avid site, and adequate autologous stem cells. Patients received MIBG 18 mCi/kg on day 1 and autologous stem cell on day 15...
July 16, 2021: Journal of Clinical Oncology
Jonathan W Friedberg
No abstract text is available yet for this article.
July 16, 2021: Journal of Clinical Oncology
Sant P Chawla, Brian A Van Tine, Seth M Pollack, Kristen N Ganjoo, Anthony D Elias, Richard F Riedel, Steven Attia, Edwin Choy, Scott H Okuno, Mark Agulnik, Margaret von Mehren, Michael B Livingston, Vicki L Keedy, Claire F Verschraegen, Tony Philip, G Chet Bohac, Sergey Yurasov, Adam Yakovich, Hailing Lu, Michael Chen, Robert G Maki
PURPOSE: CMB305 is a heterologous prime-boost vaccination regimen created to prime NY-ESO-1-specific CD8 T-cell populations and then activate the immune response with a potent TLR-4 agonist. This open-label randomized phase II trial was designed to investigate the efficacy and safety of adding the CMB305 regimen to atezolizumab (anti-programmed death ligand-1 therapy) in comparison with atezolizumab alone in patients with synovial sarcoma or myxoid liposarcoma. PATIENTS AND METHODS: Patients with locally advanced, relapsed, or metastatic synovial sarcoma or myxoid liposarcoma (any grade) were randomly assigned to receive CMB305 with atezolizumab (experimental arm) or atezolizumab alone (control arm)...
July 14, 2021: Journal of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"